Frank DAmelio - Zoetis Independent Director

ZTS Stock  USD 178.71  1.75  0.99%   

Director

Mr. Frank A. DAmelio is Independent Director of the Company. Mr. DAmelio previously served as Pfizers Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. From November 2006 to August 2007, Mr. DAmelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at AlcatelLucent, S.A., a global telecommunications equipment company. Prior to the merger of Alcatel and Lucent Technologies in 2006, Mr. DAmelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent and in 2004 was promoted to be Executive Vice President, Chief Administrative Officer and Chief Financial Officer and helped lead the company through one of the most challenging periods in the telecom industrys history and returned the company to profitability. In this role, Mr. DAmelio was responsible for management and oversight of all financial, accounting, real estate and labor relations operations and the operational aspects of the legal and human resources organizations. Mr. DAmelio currently serves as a member of the board of Humana Inc., a health care company that offers a wide range of insurance products and health and welfare services. He also serves on the board of the Independent College Fund of New Jersey, and formerly served as a member of the National Advisory Board of JPMorgan Chase Co. Mr. DAmelio earned his MBA in Finance from St. Johns University and his bachelors degree in Accounting from St. Peters College. Mr since 2016.
Age 63
Tenure 8 years
Professional MarksMBA
Address 10 Sylvan Way, Parsippany, NJ, United States, 07054
Phone973 822 7000
Webhttps://www.zoetis.com
D’Amelio earned his MBA in Finance from St. John’s University and his bachelor’s degree in Accounting from St. Peter’s College.

Zoetis Management Efficiency

The company has Return on Asset of 0.1466 % which means that on every $100 spent on assets, it made $0.1466 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.473 %, implying that it generated $0.473 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.
Zoetis Inc has 6.75 B in debt with debt to equity (D/E) ratio of 1.48, which is OK given its current industry classification. Zoetis Inc has a current ratio of 2.14, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Zoetis to invest in growth at high rates of return.

Similar Executives

Showing other executives

DIRECTOR Age

Rolf ClassonCatalent
75
Aarti ShahElanco Animal Health
55
Christa KreuzburgCatalent
61
Thomas RossBausch Health Companies
69
David RicksElanco Animal Health
52
George JoulwanEmergent Biosolutions
80
Yoshiaki FujimoriTakeda Pharmaceutical Co
69
Kirk McDonaldElanco Animal Health
54
Richard SchutterBausch Health Companies
79
Kapila AnandElanco Animal Health
67
Faysal KalmouaAlvotech
48
Russel RobertsonBausch Health Companies
72
Roberto MignoneTeva Pharma Industries
48
Gregory LucierCatalent
56
Kathryn ZoonEmergent Biosolutions
71
Amy WechslerBausch Health Companies
50
Ronald RichardEmergent Biosolutions
64
Denise ScotsKnightElanco Animal Health
61
JeanMichel HalfonTeva Pharma Industries
68
John GreischCatalent
65
Koji HatsukawaTakeda Pharmaceutical Co
68
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 12100 people. Zoetis Inc (ZTS) is traded on New York Stock Exchange in USA. It is located in 10 Sylvan Way, Parsippany, NJ, United States, 07054 and employs 14,100 people. Zoetis is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Zoetis Inc Leadership Team

Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Steven Frank, Vice Relations
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Timothy Bettington, Executive Vice President and President U.S. Operations
Ester Banque, Executive Operations
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications
Sanjay Khosla, Independent Director
William Price, VP Officer
Jamie Brannan, Executive Diagnostics
Catherine Knupp, Executive Vice President, President - Research and Development
Jeannette Astorga, Executive Officer
Michael McCallister, Non-Executive Independent Chairman of the Board
Wetteny CPA, Executive CFO
Paul Bisaro, Independent Director
Antoinette Leatherberry, Independent Director
Nick Ashton, Executive Supply
Willie Reed, Independent Director
William Dorsey, Vice Diagnostics
Rimma Driscoll, Commercial Strategy
Glenn David, Chief Financial Officer, Executive Vice President
Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development
Robert Kelly, Executive Vice President and President International Operations
J McFarland, Executive Vice President and Chief Medical Officer
Keith Sarbaugh, Executive Officer
Robert Polzer, Executive Vice President and Presidentident of Research and Development
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses
Julie Fuller, Chief VP
Juan Alaix, Chief Executive Officer, Director

Zoetis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Zoetis Stock Analysis

When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.